A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

A new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and the uncertainty surrounding three unproven therapeutics were portrayed by ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Interest in the anti-parasitic drug ivermectin skyrocketed during the covid-19 pandemic, but evidence for many of its ...

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...

Stratified analyses revealed a notable increase in risk among cancer survivors aged 50 years or older at baseline (aHR, 1.85) ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19/influenza shot.

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

In spite of having plagued humans for millennia, typhoid fever is rarely considered in developed countries today. But this ancient threat is still very much a danger in our modern world. According to ...